5 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow this condition Literature Review of Locally Advanced Gastroesophageal Junction Adenocarcinoma trials Research Report on Locally Advanced Gastroesophageal Junction Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-19 |
| Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 40 | 2023-03-07 | 2025-12-16 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Oxaliplatin+S-1, Sinitilimab+oxaliplatin+S-1 - Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 302 | 2021-09-01 | 2021-08-04 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate - Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 45 | 2021-06-08 | 2026-05-04 |
| Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Docetaxel, Fluorouracil, Oxaliplatin - Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 16 | 2020-09-16 | 2026-08-13 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
Neoplasm Metastasis (3) · Adenocarcinoma Of Esophagus (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Stomach Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Squamous Cell (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Diseases (2)
Specimen Handling (4) · pembrolizumab (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Fluorouracil (2) · Oxaliplatin (2) · dehydroftorafur (2) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Docetaxel (1) · Immunoglobulin G (1) · Leucovorin (1) · Paclitaxel (1) · Propranolol (1) · Radiation (1)
Mayo Clinic (2) · Roswell Park Cancer Institute (2) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1)
United States (7) · China (1)
Christos Fountzilas, MD (1) · Funda Meric-Bernstam (1) · Gladys Rodriguez, MD (1) · Jaffer A Ajani (1) · Jun-Sheng Peng, Dr (1) · Kannan Thanikachalam (1) · Mojun Zhu, M.D. (1) · Yanyan Lou, MD, PhD (1)
P30CA060553 (1), R37CA282430 (1), UM1CA186688 (1)